Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRON NASDAQ:SLS NASDAQ:TLRY TSE:VBV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.60+1.6%$2.12$1.60▼$2.77$980.58M1.013.09 million shs2.79 million shsSLSSELLAS Life Sciences Group$1.91+8.5%$1.79$0.77▼$2.27$185.32M2.261.77 million shs2.16 million shsTLRYTilray Brands$1.15+3.6%$0.66$0.35▼$1.95$1.22B1.8576.17 million shs51.16 million shsVBVVBI VaccinesC$0.00C$3.85▼C$7.60C$308.86MN/A3,637 shs1,300 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.56%+9.70%+24.40%+28.08%+8.79%SLSSELLAS Life Sciences Group+8.52%+17.18%+3.80%+1.06%+45.80%TLRYTilray Brands+3.60%+11.65%+56.23%+159.95%-39.15%VBVVBI Vaccines0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group0.7663 of 5 stars0.03.00.00.02.00.01.3SLSSELLAS Life Sciences Group2.9108 of 5 stars3.52.00.00.03.81.70.6TLRYTilray Brands2.6666 of 5 stars3.11.00.00.03.81.71.3VBVVBI VaccinesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 3.00Buy$7.00266.49% UpsideTLRYTilray Brands 2.20Hold$1.9266.67% UpsideVBVVBI Vaccines 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VBV, TLRY, CRON, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025TLRYTilray BrandsZelman & AssociatesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.00(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.61M8.47$0.00 per share5,501.59$2.95 per share0.88SLSSELLAS Life Sciences Group$1M201.12N/AN/A$0.25 per share7.64TLRYTilray Brands$821.31M1.54$0.15 per share7.68$1.40 per share0.82VBVVBI VaccinesC$3.36M0.00N/AN/AC$1.01 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group$41.08M$0.0552.0086.67N/A14.19%-3.78%-3.62%N/ASLSSELLAS Life Sciences Group-$30.88M-$0.32N/AN/AN/AN/A-132.51%-92.79%N/ATLRYTilray Brands-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)VBVVBI VaccinesN/A-C$0.97N/AN/AN/AN/AN/AN/AN/ALatest VBV, TLRY, CRON, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767-$0.07+$0.0067-$0.07N/AN/A8/7/2025Q2 2025CRONCronos Group-$0.02-$0.10-$0.08-$0.10$45.73 million$33.46 million7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/AVBVVBI VaccinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.6523.53SLSSELLAS Life Sciences GroupN/A4.914.91TLRYTilray Brands0.202.461.49VBVVBI Vaccines14.292.642.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%SLSSELLAS Life Sciences Group17.38%TLRYTilray Brands9.35%VBVVBI VaccinesN/AInsider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%SLSSELLAS Life Sciences Group1.40%TLRYTilray Brands0.60%VBVVBI VaccinesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450383.04 million355.08 millionOptionableSLSSELLAS Life Sciences Group10105.30 million103.82 millionNot OptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableVBVVBI Vaccines2264.08 millionN/ANot OptionableVBV, TLRY, CRON, and SLS HeadlinesRecent News About These CompaniesDecades of research push cytomegalovirus vaccine closer to realityJanuary 7, 2025 | msn.comFive Covid-19 vaccine false theories - debunkedOctober 26, 2024 | bbc.co.ukVBIVQ VBI Vaccines Inc.August 15, 2024 | seekingalpha.comVBI Vaccines Inc. (Nasdaq: VBIV) Rises from the Ashes and is NASDAQ Top Percentage GainerAugust 6, 2024 | investorideas.comIVBI Vaccines Starts Restructuring Procedure in CanadaJuly 30, 2024 | marketwatch.comVBI Vaccines secures court protection as it restructures, seeks buyer(s)July 30, 2024 | fiercebiotech.comFVBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023April 16, 2024 | msn.comVBI Vaccines sells hepatitis B vaccine candidate, manufacturing digs to partner Brii Biosciences for up to $33 millionFebruary 14, 2024 | fiercepharma.comFThe Truth About VaccinesJanuary 6, 2024 | webmd.comWVBI Vaccines Inc VBIVOctober 31, 2023 | morningstar.comMAccess to new Covid-19 vaccines delayed for Vermonters on MedicaidSeptember 27, 2023 | vtdigger.orgVNo, Pfizer COVID-19 vaccine doesn't cause 'VAIDS.' That's not a real condition | Fact checkSeptember 26, 2023 | usatoday.comAvailability of new 2023–2024 COVID-19 vaccine in VirginiaSeptember 26, 2023 | newsleader.comNThe Consumer’s Guide to RSV Vaccines for Older AdultsSeptember 24, 2023 | everydayhealth.comEUpdated COVID-19 vaccine recommended for everyone; old, young, immunocompromised will benefit mostSeptember 23, 2023 | usatoday.comIs It Safe to Get Multiple Vaccines at the Same Time?September 22, 2023 | everydayhealth.comEThe real data behind the new COVID vaccines the White House is pushingSeptember 21, 2023 | nypost.comNNew COVID vaccines will be available in RI. Here's how to get one.September 20, 2023 | providencejournal.comPCOVID vaccine pill that kills virus before it infects the body could be comingSeptember 15, 2023 | nypost.comNInterim results show Brii’s therapeutic HBV vaccine induces immune responseSeptember 8, 2023 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025Deeply Undervalued, Micron Technologies Stock Isn’t Pricing in AIBy Thomas Hughes | August 14, 2025Micron Stock Still Cheap Despite 25% Rally, Analysts SayBy Gabriel Osorio-Mazilli | August 19, 2025Tilray's High Hopes: The Catalyst Driving Cannabis StocksBy Jeffrey Neal Johnson | August 21, 2025VBV, TLRY, CRON, and SLS Company DescriptionsCronos Group NASDAQ:CRON$2.60 +0.04 (+1.56%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.61 +0.01 (+0.23%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.SELLAS Life Sciences Group NASDAQ:SLS$1.91 +0.15 (+8.52%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.90 -0.01 (-0.52%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Tilray Brands NASDAQ:TLRY$1.15 +0.04 (+3.60%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.VBI Vaccines TSE:VBVVBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access